Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Obesity‐induced insulin resistance and type 2 diabetes mellitus can ultimately result in
various complications, including diabetic cardiomyopathy. In this case, cardiac dysfunction is …

Heart failure is a systemic syndrome caused by multiple pathological factors. Current
treatments do not have satisfactory outcomes. Several basic studies have revealed the …

Abnormalities of myocardial energy metabolism appear as a common background of the two
major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). Myocardial …

Abstract Ischemia/reperfusion (I/R) injury is a tissue damage during reperfusion after an
ischemic condition. I/R injury is induced by pathological cases including stroke, myocardial …

We systematically searched the literature to assess the efficacy of trimetazidine in reducing
periprocedural myocardial injury and improving postoperative left ventricular ejection …

Purpose Trimetazidine, a metabolic agent with anti-ischemic effects, was reported to reduce
reperfusion injury in animal models. In this randomized double-blind placebo-controlled trial …

Aims. Trimetazidine (TMZ) is effective at improving clinical outcomes in chronic heart failure
and stable coronary artery disease patients. However, no single study has comprehensively …

目的建立糖尿病大鼠动物模型, 探讨曲美他嗪对糖尿病大鼠心肌组织氧化应激水平和内质网应激
水平的影响. 方法将30 只健康雄性SD 大鼠随机平均分为对照组(C 组), 糖尿病组(DM 组) …

Objective. To evaluate the myocardial protection of Ivabradine (IBD) combined with
Trimetazidine (TMZ) in patients with coronary artery disease (CAD) after percutaneous …